NDAINTRAVENOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLINVYK (oliceridine) is an intravenous opioid analgesic approved by the FDA in August 2020 for the treatment of acute pain in hospital settings. It is a small-molecule mu-opioid receptor agonist administered as an IV solution. The drug represents a newer generation opioid option for perioperative and acute care pain management.
Peak5.9 years to LOE
Product is in peak commercial phase with opportunity for field-based commercial roles, though market penetration and team size remain undisclosed.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Started May 2016
418 enrolled
Acute Pain
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Started May 2016
407 enrolled
Acute Pain
Career Relevance
OLINVYK offers career opportunities primarily in hospital-focused commercial roles, with emphasis on acute care penetration and clinical engagement. However, the product's limited market traction (zero linked jobs in available data) and significant competitive pressure from entrenched oral opioids suggest a niche role with moderate growth potential.
Worked on OLINVYK at Trevena? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.